Chardan Healthcare Acquisition Corp. (CHAC), recently announced that its shareholders have approved their business combination with BiomX Ltd. (“BiomX”), a microbiome company developing both natural and engineered phage therapies. More than 97% of the shares voted today were voted in favor of the proposed transaction with BiomX.
The transaction is expected to close on October 28, 2019, and the combined company will be renamed BiomX Inc. The shares, units, and warrants are expected to trade on the NYSE American on October 29, 2019 under the symbols PHGE, PHGE.U, and PHGE.WS, respectively.
Additional details, such as the number of redemptions, will subsequently be filed in an 8-K, so check back for that information.
- Chardan is acting as CHAC’s M&A and capital markets adviser.
- Cantor is acting as capital markets adviser to BiomX.
- Loeb & Loeb LLP and Meitar Liquornik Geva Leshem Tal are representing CHAC.
- Goodwin Procter LLP, Mayer Brown LLP and ZAG-S&W Zysman Aharoni Gayer & Co are representing BiomX.